SEC Form 4 · accession 0000899243-18-015794
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Corwin Dale Hooks
Officer — See Remarks
Period of report
Jun 6, 2018
Accepted (ET)
Jun 8, 2018 · 5:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 6, 2018 | M | 468 | — | A | 4,919 | D | |
| Common Stock | Jun 6, 2018 | F | 235 | $47.70 | D | 4,684 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3,F1 | — | Jun 6, 2018 | M | 468 | D | — | — | Common Stock | 468 | 5,157 | D |
Explanation of responses
- F1Each restricted stock unit represents the right to receive one share of Common Stock.
- F2The reporting person filed a Form 4 on June 1, 2018, reporting the conversion of 869 Restricted Stock Units into shares of Common Stock. The amount of securities beneficially owned following this transaction contained a clerical error, and should have been 4,895. The amount of securities beneficially owned after taking into account the second transaction reported on June 1, 2018 remains correct.
- F3On March 27, 2017, the reporting person was granted 7,500 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Remarks
Senior Vice President and Chief Commercial Officer